Validation of developed analytical method for moxifloacin floating tablets by reverse phase high performance liquid chromatography

Abstract

Aimofthepresentinvestigationwastovalidateanewanalytical,simple,sensitive, selective and precise High Performance Layer Chromatographic (HPLC) method for the estimation of Moxifloacin in tablet dosage form. Moxifloacin is chemically1-7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid. The mobile Phase comprised of Methanol: water (350:650) and set at a flow rate of 1.2ml/minute. Detection was carried out at 293nm using pre-packed Symmetry C₁₈; 250x4.6mm, 5µm particle size column. Detection was carried out at 222nm using pre-packed Symmetry C₁₈; 250x4.6mm, 5µm particle size column. The retention time of Moxifloacin was found to be 1.825. The assay was linear over concentration range of 12.5µg/ml to 75µg/ml (R=0.99995). The limit of detection and the limit of quantification were found to be 2.68µg/ml and 4.46µg/ml respectively. The amount of Moxifloacin was found to be 100.229±0.47 and the accuracy of Moxifloacin was found to be 99.460% to 100.369%. The statistical analysis of the data showed that the method is reproducible and selective for the estimationof Moxifloacinin tablet dosage form during routine analysis.